{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:28:01Z","timestamp":1790756881792,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P 30-EY026877"],"award-info":[{"award-number":["P 30-EY026877"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ophtha.2026.05.028","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T23:34:30Z","timestamp":1779838470000},"page":"1185-1194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ocular Inflammation as a Risk Factor for Antiadalimumab Antibodies in Patients with Autoimmune Diseases Treated with Adalimumab"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2907-0050","authenticated-orcid":false,"given":"Osama","family":"Elaraby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"El-Feky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Akhavanrezayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelaziz","family":"Abdelaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Yavari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishaan","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Ni","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Xian","family":"Thng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anadi","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunay Uludag","family":"Kirimli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Bagher","family":"Rajabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Bazojoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cigdem","family":"Yasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmak","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Awatramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Mobasserian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc Trong Tuong","family":"Than","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-8441","authenticated-orcid":false,"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ophtha.2026.05.028_bib1","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ajg.2009.59","article-title":"Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn\u2019s disease: results from the CHARM trial","volume":"104","author":"Colombel","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ophtha.2026.05.028_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.ophtha.2026.05.028_bib3","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ophtha.2026.05.028_bib4","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ophtha.2026.05.028_bib5","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10050","key":"10.1016\/j.ophtha.2026.05.028_bib6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ophtha.2026.05.028_bib7","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2026.05.028_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/09273948.2018.1491605","article-title":"Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II trials","volume":"27","author":"Goto","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.ophtha.2026.05.028_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"issue":"14","key":"10.1016\/j.ophtha.2026.05.028_bib10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ophtha.2026.05.028_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e29313","article-title":"Risk factors for development of anti-adalimumab antibodies in non-infectious uveitis","volume":"10","author":"Bromeo","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ophtha.2026.05.028_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ajo.2024.12.009","article-title":"High body mass index is associated with lower adalimumab serum levels and higher disease activity in noninfectious uveitis","volume":"271","author":"Pichi","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.05.028_bib13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ajo.2024.09.008","article-title":"Adalimumab drug monitoring and treatment adjustment to drug antibodies in noninfectious uveitis","volume":"268","author":"Pichi","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ophtha.2026.05.028_bib14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/09273948.2023.2256850","article-title":"Immunogenicity of adalimumab in patients with non-infectious uveitis: systematic review and meta-analysis","volume":"32","author":"Pach\u00f3n-Su\u00e1rez","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"10.1016\/j.ophtha.2026.05.028_bib15","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.ophtha.2016.08.025","article-title":"Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies","volume":"123","author":"Cordero-Coma","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2026.05.028_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jamaophthalmol.2022.5584","article-title":"Antidrug antibodies to tumor necrosis factor \u03b1 inhibitors in patients with noninfectious uveitis","volume":"141","author":"Bellur","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2026.05.028_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/annrheumdis-2013-204101","article-title":"Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects","volume":"74","author":"Krieckaert","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ophtha.2026.05.028_bib18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ajg.2011.103","article-title":"Assessing response and loss of response to biological therapies in IBD","volume":"106","author":"Yanai","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.ophtha.2026.05.028_bib19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"10050","key":"10.1016\/j.ophtha.2026.05.028_bib20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ophtha.2026.05.028_bib21","first-page":"1043","article-title":"Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis","volume":"35","author":"Leinonen","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.ophtha.2026.05.028_bib22","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bjophthalmol-2021-319072","article-title":"Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study","volume":"106","author":"Sejournet","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"7\u20138","key":"10.1016\/j.ophtha.2026.05.028_bib23","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/09273948.2021.1936565","article-title":"Anti-adalimumab antibodies in patients with non-infectious ocular inflammatory disease: a case series","volume":"30","author":"McKay","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2026.05.028_bib24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajo.2022.03.017","article-title":"Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy","volume":"240","author":"Eurelings","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ophtha.2026.05.028_bib25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nri.2017.100","article-title":"Organ-specific protection mediated by cooperation between vascular and epithelial barriers","volume":"17","author":"Spadoni","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.ophtha.2026.05.028_bib26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10067-019-04798-6","article-title":"Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching","volume":"39","author":"Brunelli","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.ophtha.2026.05.028_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41577-024-00996-9","article-title":"The conneXion between sex and immune responses","volume":"24","author":"Forsyth","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.ophtha.2026.05.028_bib28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/eva.13167","article-title":"Why women have more autoimmune diseases than men: an evolutionary perspective","volume":"14","author":"Kronzer","year":"2020","journal-title":"Evol Appl"},{"key":"10.1016\/j.ophtha.2026.05.028_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1429544","article-title":"Dynamics and implications of anti-drug antibodies against adalimumab using ultra-sensitive and highly drug-tolerant assays","volume":"15","author":"Ding","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ophtha.2026.05.028_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.ophtha.2026.05.028_bib31","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ophtha.2026.05.028_bib32","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2026.05.028_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17750355","article-title":"Immunogenicity of biologics in inflammatory bowel disease","volume":"11","author":"Vermeire","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"issue":"2","key":"10.1016\/j.ophtha.2026.05.028_bib34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cgh.2021.01.006","article-title":"Patients with low drug levels or antibodies to a prior anti\u2013tumor necrosis factor are more likely to develop antibodies to a subsequent anti\u2013tumor necrosis factor","volume":"20","author":"Casteele","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ophtha.2026.05.028_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211002682","article-title":"Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis","volume":"13","author":"Migliore","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"10.1016\/j.ophtha.2026.05.028_bib36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40744-024-00658-1","article-title":"Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-year data from SELECT-COMPARE","volume":"11","author":"Fleischmann","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"11","key":"10.1016\/j.ophtha.2026.05.028_bib37","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2026.05.028_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of TNF-inhibitors","volume":"11","author":"Atiqi","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ophtha.2026.05.028_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/s12348-025-00520-7","article-title":"Characteristics of patients who developed transient anti-adalimumab antibodies","volume":"15","author":"Elaraby","year":"2025","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"8","key":"10.1016\/j.ophtha.2026.05.028_bib40","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/art.39169","article-title":"Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis","volume":"67","author":"Jani","year":"2015","journal-title":"Arthritis Rheumatol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026003763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026003763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:29:39Z","timestamp":1789723779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642026003763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0161642026003763"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.05.028","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Inflammation as a Risk Factor for Antiadalimumab Antibodies in Patients with Autoimmune Diseases Treated with Adalimumab","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}